Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trius Therapeutics Gets DTRA Contract To Develop Novel Antibiotics
Trius said that it may receive up to $29.5m in support of development efforts under the new DTRA contract, which is funded as part of DTRA’s Transformational Medical
Trius said that it may receive up to $29.5m in support of development efforts under the new DTRA contract, which is funded as part of DTRA’s Transformational Medical
Watson Pharmaceuticals said that it has initiated the shipments of Atorvastatin Calcium tablets. Atorvastatin Calcium, used for lowering blood cholesterol, is the generic equivalent to Pfizer’s Lipitor tablets
Sentrx claimed that CROplus addresses four critical areas such as custom adverse event management, high speed drug safety implementation, embedded safety technology expertise and flexible client management reporting,
Trends towards improvement in the key neurological endpoint were however identified by a meta-analysis of all Santhera’s Phase II and III studies in the same indication. MICONOS also
Galapagos claimed that GLPG0492 is an orally available small molecule that has been developed in its Selective Androgen Receptor Modulator (SARM) program. The candidate drug has been shown
Anders Fugelli, head of business development at Lytix Biopharma provided an update on the Phase I study of Oncopore (LTX-315) for the treatment of solid tumours. Set up
Millipore said that itss BioPharma Services unit is the first CRO dedicated to large molecule bioanalytical work. The unit arose from Millipore’s acquisition in August, 2009 of BioAnaLab,
Hybrigenics said that the clinical tolerance observed at high and frequent exposure to Inecalcitol is positive. This makes it possible to consider other potential therapeutic indications such as
Inviragen’s DENVax investigational vaccine, developed by researchers at the CDC’s division of Vector-Borne Diseases, is based on an attenuated DEN-2 virus that generates long-lasting anti-dengue immune responses. CDC
The published results are from an analysis of prespecified quality of life measures from one of the large, pivotal phase III trials for Stelara, Phoenix 2. Data from